Articles tagged with Vaccine Research
A randomized, open-label bridging clinical trial was conducted to evaluate the immunogenicity and safety of a 9-valent HPV vaccine in adolescents aged 9-17 years compared to young women. The study found non-inferior immune responses with seroconversion rates comparable to those in young women receiving three doses.
Two new TB vaccines, VPM1002 and Immuvac, demonstrate safety and effectiveness in preventing progression to active TB in latent infection, particularly in children. However, they do not offer general protection against all forms of TB or prevent weight-related mortality.
Persistent inequalities remain a major barrier to achieving universal protection against life-threatening infections. The study found that PCV booster retention has dropped in England since the schedule change, disproportionately affecting children in more deprived areas.
Researchers at UW–Madison identified a way to program longer-lasting T cells, which can recognize more stable parts of viruses and offer a path to broader protection. The new strategy has the potential to provide longer-lasting immunity against respiratory infections like the flu and COVID-19.
Researchers have developed experimental compounds that block flu viruses by locking onto their surface enzyme, potentially improving treatments and pandemic preparedness. The new approach shows promise in stopping common types of flu virus, including H3N2 and bird flu strains.
The Linda and Mike Mussallem Foundation has donated to USC's Keck School of Medicine to enhance clinical trials for individuals with Down syndrome at risk for Alzheimer's. This will increase domestic and international sites, accelerating the development of treatments specifically for this population.
Researchers discovered a new layer of defense in the lungs, where specialized immune cells coordinate a local response to viral infections. The study found that these cells produce a protein called HIF-1α, which activates neighboring immune cells to mount a coordinated defense.
Researchers redesigned a key component of lipid nanoparticles to steer particles toward lymph nodes, reducing off-target delivery. This advancement could make mRNA vaccines more efficient, potentially achieving strong immune protection at lower doses.
Researchers at the University of Pennsylvania developed lipid nanoparticles that modify immune metabolism to strengthen mRNA vaccines and reduce common side effects. The new lipid boosts the metabolism of immune cells, providing energy for the body's defenses while dialing down inflammatory signals.
A recent study found that people with atherosclerotic heart disease who received the shingles vaccine had nearly half the rate of serious cardiac events compared to those who did not get vaccinated. The vaccine was associated with significant reductions in cardiovascular risk, including heart attacks, strokes, and death.
A Simon Fraser University study found cultural, administrative, and governance barriers reinforce mistrust and limit vaccine access. Community-led clinics and trusted messengers can increase access and trust, but remain underfunded and excluded from decision-making.
A new study discovered that a multifaceted infection prevention and control intervention successfully disrupted a large and long-running bacterial outbreak of Klebsiella pneumoniae in a Zambian neonatal intensive care unit. The study found that low-cost measures, including IPC training, enhanced cleaning, and hand hygiene, reduced neon...
A Purdue University-developed contraceptive vaccine reduces fertility in feral horses, deer, swine, and other animals, overcoming limitations of existing models. The vaccine, based on a male sperm protein, induces a long-lasting immune response and infertility in female mammals, with promising results for wildlife management.
A randomized, double-blind clinical trial found that a natural fungal supplement, FoTv, reduced short-term vaccine side effects and helped antibodies last longer in people who had not previously been exposed to COVID-19. The study suggests that FoTv may help strengthen vaccine protection without increasing side effects.
The American College of Physicians advises all adults aged 75 or older to receive a protein subunit Respiratory Syncytial Virus (RSV) vaccine, reducing the risk of severe illness and hospitalization. Adults aged 60-74 with comorbid conditions may also consider receiving the vaccine. The benefits outweigh the harms in this age group.
Researchers at the University of Texas at Austin have created a high-resolution 3D map of the Andes virus, a crucial step towards developing vaccines and treatments against hantaviruses. The new structure allows for the design of effective vaccines and antibody therapies.
A novel vaccination approach cleared harmful gut bacterium Clostridioides difficile (C. diff) in an animal model of infection. The experimental vaccine protected against illness, death, tissue damage and infection recurrence through mucosal immunization.
A new study has shown that hospital analysers can accurately distinguish genuine liquid medical products from fakes, providing a low-cost screening tool to complement established methods. This breakthrough addresses a global health threat, with an estimated 10.5% of medicines worldwide being substandard or fake.
Researchers at Ragon Institute discovered that antibodies produced in germinal centers act as a 'brake' on selection, redirecting the immune system toward broader protection. Stronger-binding B cells suppress weaker ones targeting the same site, establishing a localized feedback loop.
A newly described HIV antibody targets the V3 glycan site in a different manner than previously known antibodies, remaining effective against virus variants that are resistant to classical V3 antibodies. This breakthrough supports antibody therapy combinations that neutralize the virus more effectively.
The VALIDATE Network has achieved significant milestones in global collaboration for vaccine research, with over £3.5M in grants and £25.5M in follow-on funding secured. The network has supported over 86 novel publications and delivered online seminars and workshops to more than 3,400 attendees.
Researchers have identified a molecular trigger for rare blood clotting conditions after COVID19 adenovirus-based vaccines or natural adenovirus infections. The exact cause is now understood, allowing vaccine developers to adjust the adenovirus protein and prevent this extremely rare reaction.
A new HPV cancer vaccine developed by Northwestern University scientists has shown promising results in a preclinical model. The vaccine's carefully organized structure dramatically enhances the immune system's ability to attack tumors, shrinking them and extending animal survival.
Researchers developed a PD-L1-binding antigen presenter that redirects antiviral antibodies to target cancer cells, transforming virus-specific immune memory into precision anti-cancer weapons. This strategy has significant potential for treating hard-to-treat cancers and represents a lower-cost, safer avenue for tumor immunotherapy.
The partnership aims to develop next-generation mRNA vaccines with enhanced stability and targeted delivery, providing broader protection against emerging pathogens. This collaboration combines Ethris' mRNA technology platforms with DZIF's vaccine research expertise to accelerate the development of variant-ready vaccines.
A team of researchers at Binghamton University is developing a new yeast-based solution for the production of better avian flu vaccines. The project aims to improve manufacturing, storage, and transportation efficiency compared to current options.
Researchers at MIT and Scripps Research Institute have developed a vaccine that generates a significant population of rare precursor B cells capable of evolving to produce broadly neutralizing antibodies against HIV. The DNA-VLP approach shows potential for inducing broadly neutralizing antibody responses against influenza as well.
Researchers developed an intranasal vaccine that elicited strong immune responses and prevented infections in exposed animals, providing protection against upper respiratory infection and severe disease. The nasal vaccine was effective regardless of prior flu exposure, making it a promising tool in the fight against H5N1 bird flu.
The new platform developed by UVA Health scientists can produce vaccines much faster, cheaper, and more easily than traditional approaches. The platform's proof-of-concept demonstrates its ability to produce highly immunogenic vaccines that can be manufactured at extremely low cost.
A new foot-and-mouth disease vaccine developed by Diamond Light Source is projected to deliver over $1.3 billion in annual benefits, transforming global livestock resilience. The vaccine's unique features, including heat stability and scalability, make it a game-changer for farmers worldwide.
A study found that vaccinating pregnant women increases protection for infants against whooping cough, a highly contagious disease. The research team also showed that whole-cell pertussis vaccines provide longer-lasting protection than acellular vaccines, and recommends vaccination during pregnancy as a double-layered defense.
A single-dose oral cholera vaccine called PanChol has completed a phase 1 clinical trial with positive results, offering hope for combating the devastating disease globally. The vaccine was developed by Mass General Brigham and shows promise in preventing severe vomiting and diarrhea caused by Vibrio cholerae bacteria.
A Cornell psychology professor argues that people make decisions based on intuition and core values rather than facts. Research found that considering the overall sense of risks and benefits (or
A new study published in JAMA Oncology found that the HPV vaccine can protect against severe precancerous lesions of the vulva and vagina. Vaccination before the age of 17 offers the strongest protection, with a 55% lower risk compared to unvaccinated women.
A new white paper by biostatistician Professor Jeffrey S. Morris analyzes the multicomponent US vaccine safety monitoring system, including VAERS and other components. The study suggests improvements to enhance the system's effectiveness and sustain a robust safety monitoring infrastructure.
Researchers used AI to identify a new viral surface protein that triggers the production of neutralizing antibodies, offering a breakthrough for developing effective vaccines and antibody therapies. The discovery could also provide insights into treating smallpox, a related virus posing a bioterrorism risk.
A survey study found that US voters generally support government role in ensuring safe vaccines, with high partisan divide among Trump and Harris supporters. Vaccine requirements for schools show similar support across parties.
A national survey of adults found that three-quarters support vaccinating newborns against hepatitis B, but Republicans are less likely to recommend the vaccine. The survey also found that most respondents believe the vaccine protects against liver disease, and there is little evidence justifying delaying vaccination.
A Finnish study published in Nature Microbiology found that the MF59-adjuvanted A(H5N8) vaccine induced strong immune responses against the vaccine virus and heterologous H5 strains. The majority of participants developed seroprotective antibody levels after two doses, with significant increases in T-cell responses.
A new organ-on-a-chip platform recapitulates age-dependent immune responses, allowing for more accurate testing of cancer vaccines in older adults. The platform reveals functional differences in immune responses between young and old lymphocytes, which are not detectable with traditional 2D cultures.
Researchers have found that early-infancy RSV infection significantly increases the risk of developing childhood asthma, especially in those with family history of allergy or asthma. Protecting newborns against RSV could substantially reduce asthma cases later in life.
A new study by ESMT Berlin finds that fractional-dose vaccines can significantly reduce infections during epidemics, especially in low-resource settings. The researchers identify vaccination policies that minimize infections while accounting for limited stockpiles and administration capacity.
Researchers tested a 'mental model' approach to counter unwarranted fears about mRNA technology. The study found that exposing people to visual models of how vaccines work and/or how cells protect DNA from foreign fragments undercuts the effect of exposure to misconceptions.
Two new Cochrane reviews show that HPV vaccines are effective in preventing cervical cancer and pre-cancerous changes, especially when given to young people before they are exposed to the virus. Girls vaccinated before the age of 16 were found to be 80% less likely to develop cervical cancer.
Scientists have developed a fast-acting and long-lasting vaccine against Crimean-Congo hemorrhagic fever (CCHF), which is one of the world's most dangerous infectious diseases. The vaccine, made from a virus-like replicon particle, provides durable humoral immunity for up to 18 months.
The partnership aims to co-develop and evaluate next-generation self-amplifying RNA (saRNA) vaccines targeting seasonal and pandemic influenza. Apriori's Octavia platform will be combined with A*STAR IDL's saRNA delivery technology to develop improved H5 influenza vaccines that anticipate infection in humans.
A new approach developed by University of Waterloo researchers uses social media posts to identify early warning signs of increasing vaccine skepticism. This method can detect patterns in data much more effectively than traditional methods, providing a bigger lead time before an outbreak occurs.
This book explores the evolution of patent protection in vaccinology and its impact on vaccine distribution and research collaboration. It highlights the need for balanced IP systems to encourage scientific progress while ensuring public health equity.
Leading experts urge universal hepatitis B vaccination for all newborns in the US, citing a 95% decline in infant infections since 1991. The policy has prevented an estimated one million hospitalizations and 90,000 deaths.
The Vaccine Innovation Center at Korea University College of Medicine has been selected as the lead institution for a health security research initiative focused on developing broad-spectrum antiviral agents and combination therapies to prevent severe disease in future pandemics. The project aims to create advanced therapeutics capable...
A comprehensive review of over 25 years of research on non-specific vaccine effects reveals no evidence to support the claim that vaccines protect against diseases other than the ones they are designed to prevent. The study, which analyzed 13 randomized trials, shows that prominent researchers have systematically over-interpreted the f...
The Phase 3 study demonstrated the safety and non-inferiority of EuTYPH-C Inj.® Multi-dose compared to a World Health Organization (WHO) prequalified comparator TCV, Typbar TCV®. The vaccine was shown to be well-tolerated across all age groups with no serious adverse events.
A new nasally-delivered vaccine has been shown to prevent severe disease and curb bacterial transmission, addressing a global need for next-generation immunisation technologies. The vaccine targets the respiratory mucosa, providing stronger protection against respiratory infections.
Researchers at the University of Pittsburgh have developed a skin patch test that can detect antibodies associated with COVID and flu infections. The test uses carbon nanotubes and is orders of magnitude more sensitive than existing tests.
Researchers have developed particles that can deliver an effective immune response at a much lower dose than traditional mRNA vaccines. The new particles, called AMG1541, use cyclic structures and ester groups to enhance mRNA delivery and improve biodegradability. This could potentially reduce vaccine costs and side effects.
Researchers at MIT have identified possible antigens for a new TB vaccine, stimulating a strong immune response in T cells. The study reveals 27 TB peptides that appear most often on infected cell surfaces and elicit a T cell response in at least some samples.
Researchers have discovered that human astroviruses bind to a protein in human cells called the neonatal Fc receptor. The study provides a key target for vaccine development and repurposing of existing treatments.
A new analytical tool using Raman spectroscopy enables rapid monitoring of vaccine quality and quantity, with results in 30 seconds or less. The tool operates on the production line, saving time and money in vaccine production.
Scientists have characterized lipid nanoparticles' internal shape and structure, which correlates with how well they deliver therapeutic cargo. The research provides a blueprint for engineering more effective RNA therapies by matching LNP designs to specific therapies and tissues.
Patients with advanced lung and skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy drugs lived significantly longer. The vaccine was associated with a near doubling of median survival, from 20.6 months to 37.3 months in lung cancer patients.